Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) Research & Development (2023 - 2025)

Biofrontera (BFRI) has 3 years of Research & Development data on record, last reported at $855000.0 in Q3 2025.

  • For Q3 2025, Research & Development rose 27.8% year-over-year to $855000.0; the TTM value through Sep 2025 reached $3.7 million, up 177.45%, while the annual FY2024 figure was $2.1 million, 2612.99% up from the prior year.
  • Research & Development reached $855000.0 in Q3 2025 per BFRI's latest filing, down from $870000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $1.2 million in Q1 2025 and bottomed at $17000.0 in Q1 2024.
  • Average Research & Development over 3 years is $565222.2, with a median of $669000.0 recorded in 2024.
  • The widest YoY moves for Research & Development: up 7000.0% in 2025, down 27.8% in 2025.
  • A 3-year view of Research & Development shows it stood at $33000.0 in 2023, then soared by 2272.73% to $783000.0 in 2024, then increased by 9.2% to $855000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $855000.0 in Q3 2025, $870000.0 in Q2 2025, and $1.2 million in Q1 2025.